SI-BONE, Inc. (SIBN) Bundle
A Brief History of SI-BONE, Inc. (SIBN)
Company Formation
SI-BONE, Inc. was founded in 2008, primarily focusing on the development of innovative solutions for the treatment of sacroiliac (SI) joint disorders. The company aims to address the significant unmet need in this area of orthopedic care.
Initial Funding and Growth
In its early stages, SI-BONE secured a Series A financing round in 2008, raising approximately $4 million. The company continued to attract attention and funding, achieving a Series B financing round in 2010, which raised an additional $9 million.
Product Development and Regulatory Milestones
SI-BONE achieved a major milestone in 2011 with the FDA clearance for its iFuse Implant System, designed for minimally invasive surgery to treat SI joint dysfunction. This system was a cornerstone of the company's product portfolio and established its presence in the medical device market.
Market Expansion
By 2014, SI-BONE had expanded its clinical data and established further credibility within the orthopedic community. The iFuse Implant System was included in various clinical studies and was presented at several key conferences, cementing its reputation.
Initial Public Offering
SI-BONE went public on October 15, 2018, trading on the NASDAQ under the ticker symbol SIBN. The IPO was priced at $15 per share, raising approximately $66 million. The success of the IPO allowed SI-BONE to accelerate its growth strategy and expand its product offerings further.
Recent Financial Performance
| Year | Revenue (in millions) | Gross Profit (in millions) | Net Income (in millions) | Market Capitalization (as of October 2023, in millions) |
|---|---|---|---|---|
| 2020 | $40.6 | $34.2 | ($15.8) | $255 |
| 2021 | $55.1 | $46.8 | ($8.6) | $400 |
| 2022 | $78.3 | $65.5 | ($1.2) | $600 |
| 2023 | $95.4 | $82.1 | $5.0 | $750 |
Recent Developments
In 2023, SI-BONE launched several new educational initiatives and clinical studies to enhance the awareness and adoption of the iFuse Implant System. The company is also focusing on expanding its international presence and exploring additional markets.
Strategic Partnerships
SI-BONE has formed various strategic partnerships throughout its history to foster innovation and expedite product development. Collaborations with leading orthopedic surgeons and research institutions have been pivotal for clinical validation and product enhancements.
Future Outlook
Looking ahead, SI-BONE aims to continue its trajectory of growth in the orthopedic market by expanding its product lines and enhancing its clinical research capabilities. The company anticipates sustained revenue growth driven by increasing demand for minimally invasive procedures.
A Who Owns SI-BONE, Inc. (SIBN)
Ownership Structure
The ownership of SI-BONE, Inc. (SIBN) comprises a combination of institutional investors, individual shareholders, and insiders. As of the latest available data, the following table summarizes the major shareholders and their respective ownership percentages:
| Shareholder Type | Shareholder Name | Ownership Percentage |
|---|---|---|
| Institutional Investor | The Vanguard Group, Inc. | 12.5% |
| Institutional Investor | BlackRock, Inc. | 10.2% |
| Individual Shareholder | Jeffrey D. Dunn | 5.8% |
| Institutional Investor | Adage Capital Management, L.P. | 8.3% |
| Insider | Michael A. O’Neill | 3.4% |
| Institutional Investor | Harris Associates L.P. | 6.7% |
| Individual Shareholder | Current Employees | 4.1% |
Market Capitalization
As of the latest financial reporting, SI-BONE, Inc. has a market capitalization of approximately $600 million. The company's stock price has exhibited significant volatility, impacting ownership percentages based on market performances.
Financial Performance
SI-BONE reported a revenue of $75 million for the fiscal year ended December 31, 2022. The company’s net income stood at $5 million, reflecting a 6.7% profit margin.
Stock Performance
As a publicly traded company, SI-BONE's stock (SIBN) has shown varying performance metrics. The closing stock price as of the latest trading day is approximately $22.5. The annual high and low prices for the stock in the past year were $30.2 and $18.6, respectively.
Insider Ownership
Insider holdings represent a significant portion of the company's stock. The table below outlines the ownership of key insiders along with their positions:
| Name | Position | Insider Ownership Percentage |
|---|---|---|
| Jeffrey D. Dunn | CEO | 5.8% |
| Michael A. O’Neill | CFO | 3.4% |
| Paula B. R. M. Garcia | COO | 1.2% |
Recent Developments
Recent market trends have shown increasing interest in the orthopedic medical device sector. SI-BONE, Inc. has expanded its product lines and collaborated with various stakeholders, leading to a projected growth in ownership stakes by institutional investors.
Conclusion of Ownership Dynamics
The landscape of ownership in SI-BONE, Inc. reflects a diverse array of investors, with substantial institutional backing and active insider participation. These elements combine to shape the financial trajectory and market presence of the company.
SI-BONE, Inc. (SIBN) Mission Statement
Corporate Overview
SI-BONE, Inc. is a pioneering medical device company dedicated to transforming the lives of patients suffering from conditions related to the sacroiliac joint. The mission statement reflects the company’s commitment to addressing unmet clinical needs through innovative technologies.
Mission Statement
The core mission of SI-BONE is to be the global leader in innovative solutions for the sacroiliac joint, ultimately improving patient outcomes and enhancing the quality of life for individuals facing debilitating pain.
Key Elements of the Mission Statement
- Innovation: Focus on developing cutting-edge surgical solutions.
- Patient-Centricity: Commitment to improving patient outcomes.
- Accessibility: Ensure that innovative treatments are widely available.
- Education: Provide comprehensive education to healthcare professionals.
Financial Performance
As of the end of 2023, SI-BONE reported a total revenue of approximately $70 million, marking a year-on-year growth of 25% compared to 2022. The company boasts a gross margin of 73%.
| Year | Revenue ($ Million) | Year-on-Year Growth (%) | Gross Margin (%) |
|---|---|---|---|
| 2020 | 45 | - | 70 |
| 2021 | 56 | 24% | 71% |
| 2022 | 56 | 0% | 72% |
| 2023 | 70 | 25% | 73% |
Product Portfolio
SI-BONE's mission also emphasizes its comprehensive product line tailored for surgical solutions in the treatment of sacroiliac joint dysfunction. The flagship product, the iFuse Implant System, has seen widespread adoption since its inception, with over 200,000 procedures performed globally.
Market Position
The company holds a market share of approximately 60% in the sacroiliac joint fusion market as of 2023. This is indicative of its strong brand presence and efficacy of its products.
Research and Development Focus
SI-BONE allocates around 15% of its annual revenue to research and development, focusing on enhancing existing products and exploring new technologies to further improve surgical outcomes.
Strategic Goals
- Expand Global Reach: Increase market penetration in Europe and Asia.
- Enhance Product Offerings: Continuously innovate with new solutions.
- Increase Awareness: Educate healthcare professionals about sacroiliac joint dysfunction.
- Improve Patient Access: Collaborate with healthcare systems to improve product availability.
Community and Sustainability
SI-BONE is committed to corporate social responsibility, participating in community health initiatives and ensuring environmentally sustainable practices across its operations.
How SI-BONE, Inc. (SIBN) Works
Company Overview
SI-BONE, Inc. is a medical device company that specializes in developing innovative solutions for the treatment of sacroiliac joint disorders. The company was founded in 2008 and is headquartered in San Jose, California.
Product Portfolio
SI-BONE offers a range of surgical implants and instruments designed for sacroiliac joint fusion. Their flagship product, the iFuse Implant System, has gained FDA approval and is widely used in minimally invasive surgeries.
Market Position
As of October 2023, SI-BONE holds a significant share of the sacroiliac joint fixation market, with approximately 40% of the market presence. The total addressable market for sacroiliac joint surgery is estimated to be around $1.5 billion.
Financial Performance
For the fiscal year ended December 31, 2022, SI-BONE reported total revenue of $92.4 million, reflecting a year-over-year growth of 31%. The gross profit for the same period was $65.5 million, with a gross margin of 71%.
Recent Financial Metrics
| Metric | Q2 2023 | Q1 2023 | Q2 2022 |
|---|---|---|---|
| Total Revenue | $24.3 million | $22.1 million | $20.7 million |
| Gross Profit | $17.5 million | $15.8 million | $14.6 million |
| Net Income | $2.4 million | $1.8 million | $1.2 million |
| Adjusted EBITDA | $5.6 million | $4.9 million | $3.7 million |
Research and Development
SI-BONE invests significantly in R&D to advance its product offerings. For the year ended December 31, 2022, R&D expenses totaled $11.2 million, representing 12% of total revenues.
Growth Strategy
- Expand sales force and marketing efforts domestically and internationally.
- Enhance product portfolio with additional indications and new products.
- Leverage partnerships with healthcare providers and institutions.
Recent Developments
In August 2023, SI-BONE received FDA clearance for an enhanced version of the iFuse Implant System, which is expected to increase adoption rates and improve patient outcomes.
Stock Performance
As of October 2023, the stock price of SI-BONE, Inc. (SIBN) is approximately $28.50 per share, with a market capitalization of around $900 million.
Investor Highlights
The company has attracted significant interest from institutional investors, and the top three institutional holders as of October 2023 include:
| Institution | Shares Held | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 2.1 million | 15% |
| The Vanguard Group, Inc. | 1.8 million | 13% |
| JP Morgan Chase & Co. | 1.5 million | 11% |
Conclusion
SI-BONE's focus on innovation, market expansion, and robust financial performance positions it as a key player in the orthopedic device market, specifically in the treatment of sacroiliac joint disorders.
How SI-BONE, Inc. (SIBN) Makes Money
Revenue Streams
SI-BONE, Inc. primarily generates revenue through the sale of its medical devices, specifically designed for the treatment of sacroiliac joint disorders and other orthopedic conditions.
Product Line Overview
The company offers a range of products, including:
- iFuse Implant System
- iFuse Bed
- iFuse 3D
- iFuse-CT
Financial Performance
As of Q2 2023, SI-BONE reported revenues of $42.5 million for the first half of the year, compared to $36.8 million in the same period of 2022.
Their annual revenue for 2022 was approximately $77.1 million, showing growth from $64.9 million in 2021.
| Year | Annual Revenue ($ Million) | Year-over-Year Growth (%) |
|---|---|---|
| 2022 | 77.1 | 18.1 |
| 2021 | 64.9 | 19.7 |
| 2020 | 54.3 | 29.5 |
Market Strategy
SI-BONE utilizes a direct sales model supplemented by partnerships with distributors to reach its target markets.
The company focuses on enhancing its sales force by increasing the number of sales representatives to improve market penetration.
Research and Development
In 2022, SI-BONE invested approximately $11.5 million in research and development, aimed at expanding its product portfolio and improving existing products.
Cost Structure
The cost of goods sold (COGS) for SI-BONE was reported at $26 million in 2022, representing 33.7% of total revenues.
Operating expenses for the same year were approximately $41 million.
| Expense Category | Amount ($ Million) |
|---|---|
| Cost of Goods Sold | 26 |
| Research and Development | 11.5 |
| Sales and Marketing | 20.5 |
| General and Administrative | 9 |
Growth Projections
Analysts forecast a compound annual growth rate (CAGR) of approximately 20% for SI-BONE over the next five years, driven by increasing adoption of their products and expanding market presence.
Conclusion on Market Position
As of mid-2023, SI-BONE holds a significant market share in the sacroiliac joint fusion market, estimated at $1.5 billion overall, with opportunities for further expansion in orthopedic markets.
SI-BONE, Inc. (SIBN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support